Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial
SUNRISE is a double-blind phase 3 trial across 63 sites in 12 countries testing whether tezepelumab reduces maintenance oral corticosteroids while preserving asthma control. Interpretation should integrate overall and eosinophil subgroups, exacerbations and safety.
Thai researchersNarongwit Nakwan